drugset / Trial / NCT07546760
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
Non-randomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.
Timeline
- Start
- 2026-03-20
- Primary completion
- 2027-02-04
- Completion
- 2027-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD6234 | Small activating RNA (saRNA) | — | Subcutaneous |
| Subject | AZD9550 | Other / unclassified | — | Subcutaneous |
Indications
No indication recorded.